Guy Innes ACA

Interim Non-Executive Chairman

Guy Archibald Innes is a Chartered Accountant and a member of the Institute of Chartered Accountants in England and Wales.

Mr. Innes has extensive experience in financing and managing technology companies, which he gained from serving as a non-executive director on the board of companies such as ProBio Inc. from 2000 to 2006, Magellan Copper & Gold Plc. from 2007 to 2010, and Carbon Mining Plc. from 2007 to 2010.

Prior to holding these directorships, Mr. Innes had a long career in banking and private equity, including advisory roles with Baring Brothers & Co. Limited in London and Paris from 1984 to 1995, where he was involved in executing and advising on national and international mergers & acquisitions, but also IPOs and capital raising; Baring Private Equity Partners Limited in London and Singapore from 1995 to 1997, where he was involved in the setting up, recruiting of managers and capital raising for an Asian media and communications private equity fund; and Quartz Capital Partners Limited from 1997 to 2000, where Mr. Innes served as Head of Corporate Finance and was responsible for managing the corporate finance department and leading the transactions undertaken by Quartz including IPOs, private placements and mergers and acquisitions.

Mr. Innes was educated at the University of Bristol (BSc Geography), and is a Member of the Institute of Chartered Accountants in England and Wales.

Cameron Reynolds MBA

President & Chief Executive Officer

Cameron is an experienced entrepreneurial executive, with expertise in biotechnology companies. He has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises.

Cameron was educated at the University of Western Australia receiving both a Bachelor of Commerce and an MBA.

Dr. Phillip Barnes

Independent Director

Dr. Barnes is a British physician with extensive experience both as a clinician and clinical manager within the UK National Health Service ("NHS") and related academic institutions. Dr. Barnes was also involved in a number of national and regional advisory groups for the Department of Health, NHS and pharmaceutical industry including being the national lead for the NHS Action On Neurology service modernization program. Dr. Barnes served as Executive Medical Director on a number of hospital and Foundation Trust Boards until his retirement from the NHS in 2016. Dr. Barnes holds a BSc and PhD from the University of London and his clinical medical degree (BM BCh) from the University of Oxford.

Dr. Alan Colman

Independent Director

Alan Colman obtained a BA degree in Biochemistry in Oxford (1971) and a PhD under John Gurdon, a pioneer of the field of nuclear transfer, at the Laboratory of Molecular Biology in Cambridge, UK (1974). After a series of academic appointments in Oxford and Warwick Universities, he became Professor of Biochemistry in the University of Birmingham, UK from 1987-1992. The focus then of his academic career was the area of eucaryotic protein secretion, with a particular emphasis on the use of frog oocytes and eggs as in vivo test tubes.

From 1987 until March 2002, he was research director of the company PPL Therapeutics in Edinburgh, UK. This company specialized in the production of transgenic livestock that produced human therapeutic proteins in their milk.  PPL attracted considerable media attention because of their use of somatic cell nuclear transfer in a collaboration with the neighboring Roslin Institute. This work led to Dolly, the world’s first sheep cloned from an adult somatic cell (1996).

From 2002-2007, he was CSO and then CEO for the Singaporean human embryonic stem cell company, ES Cell International.  Following this, he served as Executive Director of the Singapore Stem Cell Consortium and a Principal Investigator at the Singapore A*STAR Institute of Medical Biology (2006-2013) whilst concurrently Professor of Regenerative Medicine at King’s College, London, UK (2008-2009). His main research interest during these appointments was the development of human disease models using induced pluripotent stem cells.

In addition to his roles with Volition (2011- present ), Dr. Alan Colman acts as senior scientific advisor to Genea Biocells in San Diego, USA, and is a Visiting Scholar at the Harvard University Department of Stem Cell and Regenerative Biology (2014- present).

Kim Nguyen

Independent Director

Ms. Nguyen is an international HR professional with over 20 years-experience working with fast growing multinational technology companies covering Europe, Middle East & Africa, Latin America and Asia Pacific (“APAC”) markets. Ms. Nguyen currently serves as VP of International HR at a leading a blockchain company. Previously, Ms Nguyen was Head of HR for Google Asia Pacific Pte. Ltd where she led a 25-person HR team supporting over 15,000 employees across the APAC region. Ms. Nguyen holds a Bachelor of Science in Psychology (Hons) from the University of New South Wales, Sydney, Australia.

Mickie Henshall

Independent Director

Mickie is a seasoned marketing executive with over 20 years of experience in developing and implementing marketing and sales strategies within the IVD, clinical, and life science industries. Early on in her career, Ms. Henshall served as Associate Director of Diagnostics Marketing at Illumina, Inc. and has subsequently led global marketing operations at Biotix, Inc., Accriva Diagnostics, Inc. (acquired by Werfen Life), Agena Bioscience, Inc., and WGA (Genomic Life, Inc.). Mickie is currently Chief Marketing Officer at REALM IDx, Inc., a pioneering integrated diagnostics company. 

Dr. Ethel Rubin

Independent Director

Dr. Rubin has over 20 years’ experience leading healthcare innovation and commercialization strategies for both large global corporates as well as early stage operations. Over the course of her career, Dr. Rubin contributed to over 25 commercial products in the market, ranging from diagnostics, therapeutics, SaaS and devices, and was instrumental in multiple mergers and acquisitions, partnerships, collaborations and strategic initiatives. Dr. Rubin currently serves as Head of Ventures for BioHealth Innovation, Inc., a position she has held since May 2015. In this role, Dr. Rubin leads a team of strategy and finance consultants who help companies develop strategies that achieve commercial goals and valuation inflection points and who also prepare and connect companies with private capital. Earlier in her employment with BioHealth Innovation, from May 2015 to August 2018, Dr. Rubin was responsible for leading early investments for the NIH Centers for Accelerated Innovation, deploying a $45 million fund, which invested in multiple platform technologies and therapeutic assets that have gone on to raise or exit for over $1 billion. Dr. Rubin also currently serves, on a part-time basis since April 2021, as President and CEO of Mirabile Lifesci Advisory, LLC, which advises CEOs of lifesciences companies in areas related to strategic and financial planning, partnering & alliances, and technology development. From November 2009 to August 2015, Dr. Rubin held multiple leadership roles in areas such as external innovation, global clinical strategy and medical affairs at Medtronic, plc, Cardiovascular Group, where she directed the funding and/or was involved in over 100 clinical trials and research studies. Between June 2008 to May 2009, Dr. Rubin was Chief Scientific Officer of CSA Medical, Inc. (now Steris Healthcare, NYSE:STE), and from June 2004 and June 2008 was Chief Scientific & Operations Officer of BioFortis, Inc. (acquired by Q2 Solutions, an IQVIA company (NYSE:IQV), in 2018), where she played key roles in technology development and commercialization efforts for these companies. Between February 2020 and February 2023, Dr. Rubin served on the board of directors of Innara Health, Inc., a neonatal medical device company, during which time Innara completed a Series A financing and a sale to Cardinal Health in 2023 (NYSE:CAH). Dr. Rubin also served as a director of Emerging Technology Centers, Inc., a non-profit technology incubator, between May 2006 and May 2008 where she supported the center’s growth in the lifesciences space. Dr. Rubin holds a B.S. in Biochemistry from the University of Rochester, and received a Ph.D. in Biochemistry and Biophysics from the University of Rochester School of Medicine and Dentistry.